JP7495352B2 - 物理的安定性の向上および抗腫瘍効果の増強のためのミセルにおけるオリゴ乳酸コンジュゲートのステレオコンプレックス - Google Patents

物理的安定性の向上および抗腫瘍効果の増強のためのミセルにおけるオリゴ乳酸コンジュゲートのステレオコンプレックス Download PDF

Info

Publication number
JP7495352B2
JP7495352B2 JP2020553619A JP2020553619A JP7495352B2 JP 7495352 B2 JP7495352 B2 JP 7495352B2 JP 2020553619 A JP2020553619 A JP 2020553619A JP 2020553619 A JP2020553619 A JP 2020553619A JP 7495352 B2 JP7495352 B2 JP 7495352B2
Authority
JP
Japan
Prior art keywords
gemcitabine
lactic acid
gem
cancer
oligo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020553619A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520344A (ja
JPWO2019195164A5 (https=
JP2021520344A5 (https=
Inventor
グレン エス． クウォン
ユ トン タム
Original Assignee
ウイスコンシン アラムニ リサーチ ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウイスコンシン アラムニ リサーチ ファンデーション filed Critical ウイスコンシン アラムニ リサーチ ファンデーション
Publication of JP2021520344A publication Critical patent/JP2021520344A/ja
Publication of JPWO2019195164A5 publication Critical patent/JPWO2019195164A5/ja
Publication of JP2021520344A5 publication Critical patent/JP2021520344A5/ja
Application granted granted Critical
Publication of JP7495352B2 publication Critical patent/JP7495352B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020553619A 2018-04-02 2019-04-01 物理的安定性の向上および抗腫瘍効果の増強のためのミセルにおけるオリゴ乳酸コンジュゲートのステレオコンプレックス Active JP7495352B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862651365P 2018-04-02 2018-04-02
US62/651,365 2018-04-02
PCT/US2019/025174 WO2019195164A1 (en) 2018-04-02 2019-04-01 Stereocomplex of oligolactic acid conjugates in micelles for improved physical stability and enhanced antitumor efficacy

Publications (4)

Publication Number Publication Date
JP2021520344A JP2021520344A (ja) 2021-08-19
JPWO2019195164A5 JPWO2019195164A5 (https=) 2022-04-04
JP2021520344A5 JP2021520344A5 (https=) 2022-04-04
JP7495352B2 true JP7495352B2 (ja) 2024-06-04

Family

ID=66175512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020553619A Active JP7495352B2 (ja) 2018-04-02 2019-04-01 物理的安定性の向上および抗腫瘍効果の増強のためのミセルにおけるオリゴ乳酸コンジュゲートのステレオコンプレックス

Country Status (6)

Country Link
US (2) US20210128736A1 (https=)
JP (1) JP7495352B2 (https=)
KR (1) KR20200139737A (https=)
CN (1) CN112105390A (https=)
CA (1) CA3095788A1 (https=)
WO (1) WO2019195164A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110652595B (zh) * 2019-10-21 2022-11-29 南通大学附属医院 一种聚亮氨酸-聚天冬氨酸嵌段共聚物立构复合载药胶束及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017158499A1 (en) 2016-03-14 2017-09-21 Wisconsin Alumni Research Foundation Oligolactic acid conjugates and micelles with enhanced anticancer efficacy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416234D0 (en) 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
KR0180334B1 (ko) 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
JP5048690B2 (ja) * 2006-03-08 2012-10-17 クローズ 特に種子発芽および植物発生のための遅延性効果の農業処理剤
US8668919B2 (en) * 2009-03-03 2014-03-11 Abbott Cardiovascular Systems Inc. Polymer for creating hemocompatible surface
CN103599073A (zh) * 2013-11-15 2014-02-26 无锡中科光远生物材料有限公司 一种负载有靶向抗癌药物的plga微米颗粒的制备方法
CN104961786B (zh) * 2015-06-05 2018-09-25 苏州大学 基于吉西他滨结构的前体药物及其应用
WO2017201407A1 (en) * 2016-05-20 2017-11-23 Massachusetts Institute Of Technology Hydrogel particle of cystamine cross-linked dextran aldehyde containing imine conjugated doxorubicin and rgd peptide for chemotherapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017158499A1 (en) 2016-03-14 2017-09-21 Wisconsin Alumni Research Foundation Oligolactic acid conjugates and micelles with enhanced anticancer efficacy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
International Journal of Pharmaceutics，2014年，Vol.468，pp.142-151

Also Published As

Publication number Publication date
US20240207416A1 (en) 2024-06-27
JP2021520344A (ja) 2021-08-19
CN112105390A (zh) 2020-12-18
US20210128736A1 (en) 2021-05-06
KR20200139737A (ko) 2020-12-14
WO2019195164A1 (en) 2019-10-10
CA3095788A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
EP2913353B1 (en) Amphiphilic block copolymer and preparation method thereof and micellar drug-loading system formed by same with antitumor drug
CN111819217B (zh) 一种两亲性嵌段共聚物及其制备方法和纳米胶束载药系统
US9173841B2 (en) Polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, preparation method thereof, and anticancer composition for combined use with radiotherapy
CA2543722C (en) Tocopherol-modified therapeutic drug compounds
JP5981514B2 (ja) タキサン含有両親媒性ブロック共重合体ミセル組成物及びその製造方法
US10980891B2 (en) Oligolactic acid conjugates and micelles with enhanced anticancer efficacy
JP2010504960A (ja) 水難溶性カンプトテシン誘導体のサブミクロンナノ粒子及びその製造方法
US20230078391A1 (en) Pharmaceutical compositions containing mixed polymeric micelles
Dai et al. Preparation of camptothecin-loaded PCEC microspheres for the treatment of colorectal peritoneal carcinomatosis and tumor growth in mice
US20240207416A1 (en) Stereocomplex of oligolactic acid conjugates in micelles for improved physical stability and enhanced antitumor efficacy
US20230293433A1 (en) Method of manufacturing micelles for drug delivery
HK40002729A (en) Oligolactic acid conjugates and micelles with enhanced anticancer efficacy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201028

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230628

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230808

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240307

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240314

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240430

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240523

R150 Certificate of patent or registration of utility model

Ref document number: 7495352

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150